drugset / Trial / NCT02603822

Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability

NCT02603822

Phase 1 Completed 25 enrolled Mayo Clinic
NaSingle-groupOpen-labelBasic science

Summary

The investigators' overall objective with this study is to determine performance characteristics of small intestine permeability measurement using 13C mannitol and 12C (regular) mannitol.

Timeline

Start
2015-08
Primary completion
2018-07-17
Completion
2018-07-17

Drugs

EvaluationDrugModalityDoseRoute
Background Indomethacin Small molecule 75 mg